Home> Company News

E-Town solution for Cardiac electrophysiology approved for market

Updated: 2024-04-07

Beijing E-Town enterprise Synaptic Medical Technologies (Beijing) Co has obtained approval from the National Medical Products Administration (NMPA) for its AccuSafeTM transseptal puncture wire.


A researcher of Synaptic Medical conducts experiment [Photo/beijingetown.com.cn]

Cardiac electrophysiology is used for the diagnosis and treatment of arrhythmias, and guide wire has imaging capabilities. When placed inside the heart chambers, it can provide guidance for subsequent procedures such as ablation.

Addressing the clinical pain points of traditional transseptal puncture techniques, Synaptic Medical's transseptal puncture wire integrates puncture and wire functions for the first time, reducing not only surgical steps but also improving surgical efficiency. 

The needle tip made of nickel-titanium alloy material has a resistance over 90 percent lower than traditional puncture needles, resulting in a higher success rate of puncture. 

Furthermore, the "J"-shaped memory tip design after puncture avoids damage to surrounding tissues, further enhancing the safety of the product. Combined with the company's independently developed NavigoTM controllable curved sheath, puncture operations can be more precise, flexible, and efficient.

As the research and development team worked hard to overcome various technical difficulties, Synaptic Medical faced significant financial pressure in the short term. 

"At that time, Beijing E-Town helped coordinate special industrial funds for us, which made us more confident in the long-term development in the area," said a representative of Synaptic Medical.

Currently, Synaptic Medical's AccuSafeTM transseptal puncture wire has been approved for market, and nearly 60 cases have been completed in 27 centers nationwide.

According to the representatives from Synaptic Medical, it is expected that in the next two years, the number of new product registrations from Synaptic Medical would exceed 20, and the total number of registrations would reach 50, with the most prominent being the cryoablation products.

Currently, Synaptic Medical's next-generation cryo products are undergoing clinical trials in the United States, progressing very smoothly, and are expected to achieve global certification by 2025.